Onpharma addresses long-standing problems in dental anesthesia with a validated, scalable buffering platform that accelerates the broader market adoption of buffering.
Revenue is projected to grow from over $7M to $59M within three years.
The opportunity spans a large U.S. base and a growing global market, with Onpharma still in the early innings of penetration.
Onpharma has achieved approximately 1% market penetration, with a pathway to roughly 5% penetration as growth capital and the Onset EZ Pen accelerate adoption.
The category remains under-penetrated despite approximately 325 million local anesthetic injections annually across roughly 200,000 U.S. dentists.
Onpharma has moved beyond concept, with commercial validation, strong financials, and a subscrition model that supports recurring revenue.
Practices continue reordering after adoption, creating predictable revenue characteristics and strong customer economics.
Deep customer loyalty supports recurring revenue, while customer lifetime value materially exceeds acquisition cost.
Customer lifetime value of approximately $15,000 against customer acquisition cost of approximately $1,500.
The fully disposable 30-dose Onset EZ Pen simplifies adoption, training, cost per dose, and workflow integration. It also supports direct-to-dentist marketing, AI-enabled CRM automation, and a broader path to scale.
The simplified product enables direct-to-dentist marketing and AI-supported CRM automation.
Easier adoption and faster onboarding drive broader usage, conversion, and repeat consumable purchases.
Onpharma created the automated dental anesthetic buffering category and has seven years of commercial operating experience. Its brand, safety record, infrastructure, and market leadership create meaningful barriers to entry.
Onpharma built category awareness, clinical familiarity, and operating depth over time.
Compliance, commercialisation, and early market education are already in place.
Septodont's 2025 BufferPro entry validates dental anesthetic buffering and helps expand market awareness.
The Company plans to deploy growth capital across four priorities:
Expand direct-to-dentist sales in key U.S. metro markets
Deploy AI-enabled CRM and digital marketing for scalable acquisition
Build inventory safety stock and operational capacity
Increase sales coverage in key U.S. metros
Onpharma combines commercially validated products, attractive unit economics, clinical benefits, recurring revenue, and a large under-penetrated market.
Onpharma is positioned as the market leader precisely as KOLs are referring to buffering as the new Standard of Care for all 325M dental anesthetic injections delivered annually in the US.
A large, recurring, under-penetrated market with hundreds of millions of annual procedures.
Seven years of experience, $7M+ Year 0 revenue, 75% gross margin, and positive EBITDA.
The Onset EZ Pen and growth capital position the company for scalable growth.
Published Articles